Published in Leuk Lymphoma on August 22, 2012
Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leuk Lymphoma (2015) 1.52
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.85
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma (2014) 0.76
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica (2013) 0.76
"Primum non nocere": the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.75
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 11.50
Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol (2009) 8.67
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
One-sample multiple testing procedure for phase II clinical trials. Biometrics (1982) 6.45
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96
Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med (1998) 2.68
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst (1999) 2.13
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol (2008) 1.87
Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (2010) 1.58
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol (2008) 1.58
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 1.57
Effect of alemtuzumab on neoplastic B cells. Haematologica (2004) 1.46
Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc (2008) 1.30
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer (2008) 1.29
Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol (2011) 1.21
Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol (2011) 1.09
Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol (2010) 1.05
Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma (2010) 1.04
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res (2008) 1.03
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma (2004) 1.02
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol (2002) 0.97
Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol (2011) 0.96
Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica (2002) 0.93
Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma (2011) 0.90
Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia (2005) 0.86
Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma (2009) 0.84
Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol (2009) 0.82
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Systematic review of depression, anxiety, and other indicators of psychological distress among U.S. and Canadian medical students. Acad Med (2006) 5.82
Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. JAMA (2006) 5.06
Relationship between burnout and professional conduct and attitudes among US medical students. JAMA (2010) 4.34
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol (2010) 4.18
Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell (2012) 4.03
Burnout and suicidal ideation among U.S. medical students. Ann Intern Med (2008) 3.96
Association of resident fatigue and distress with perceived medical errors. JAMA (2009) 3.70
Prevalence of alcohol use disorders among American surgeons. Arch Surg (2012) 3.53
Medical student distress: causes, consequences, and proposed solutions. Mayo Clin Proc (2005) 3.46
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Personal life events and medical student burnout: a multicenter study. Acad Med (2006) 2.98
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther (2007) 2.89
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
The effects of work-hour limitations on resident well-being, patient care, and education in an internal medicine residency program. Arch Intern Med (2005) 2.63
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2007) 2.49
How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc (2005) 2.48
Burnout among U.S. medical students, residents, and early career physicians relative to the general U.S. population. Acad Med (2014) 2.47
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Quality of life, burnout, educational debt, and medical knowledge among internal medicine residents. JAMA (2011) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
A multicenter study of burnout, depression, and quality of life in minority and nonminority US medical students. Mayo Clin Proc (2006) 2.14
How do distress and well-being relate to medical student empathy? A multicenter study. J Gen Intern Med (2007) 2.10
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med (2015) 2.08
The Impact of Stigma and Personal Experiences on the Help-Seeking Behaviors of Medical Students With Burnout. Acad Med (2015) 2.06
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood (2007) 2.04
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma (2007) 1.92
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol (2014) 1.92
Relationship between work-home conflicts and burnout among American surgeons: a comparison by sex. Arch Surg (2011) 1.90
Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol (2010) 1.90
Stress and burnout among surgeons: understanding and managing the syndrome and avoiding the adverse consequences. Arch Surg (2009) 1.89
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Patterns of distress in US medical students. Med Teach (2011) 1.87
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood (2010) 1.80
The learning environment and medical student burnout: a multicentre study. Med Educ (2009) 1.79
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res (2002) 1.79
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood (2010) 1.79
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol (2002) 1.76
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
Physician satisfaction and burnout at different career stages. Mayo Clin Proc (2013) 1.75
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood (2011) 1.73
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.71
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood (2002) 1.70
Impact of resident well-being and empathy on assessments of faculty physicians. J Gen Intern Med (2009) 1.65
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol (2014) 1.65
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
Personal consequences of malpractice lawsuits on American surgeons. J Am Coll Surg (2011) 1.64
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood (2002) 1.63
Burnout and serious thoughts of dropping out of medical school: a multi-institutional study. Acad Med (2010) 1.63
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol (2010) 1.62
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood (2009) 1.61
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood (2003) 1.60
Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res (2003) 1.60
Single item measures of emotional exhaustion and depersonalization are useful for assessing burnout in medical professionals. J Gen Intern Med (2009) 1.59